Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Acquired by Rep. Gilbert Ray Cisneros, Jr.

Posted by Stanley Muller on Oct 14th, 2026

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ultragenyx Pharmaceutical stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.
Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

Ultragenyx Pharmaceutical Stock Down 2.5%

Shares of NASDAQ RARE opened at $14.92 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 52-week low of $12.73 and a 52-week high of $39.89. The business’s 50 day moving average is $19.46 and its two-hundred day moving average is $23.68. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -2.55 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. The business had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. The company’s revenue for the quarter was up 28.5% on a year-over-year basis. During the same quarter last year, the firm posted ($1.17) EPS. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.95 EPS for the current fiscal year.

Institutional Trading of Ultragenyx Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in RARE. Versant Capital Management Inc lifted its holdings in shares of Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,001 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at about $48,000. Harbor Investment Advisory LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at about $52,000. Parallel Advisors LLC grew its stake in shares of Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,440 shares in the last quarter. Finally, Leonteq Securities AG raised its holdings in shares of Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,333 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on RARE. Morgan Stanley increased their price objective on shares of Ultragenyx Pharmaceutical from $18.00 to $20.00 and gave the company an “equal weight” rating in a research report on Friday, September 18th. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. The Goldman Sachs Group decreased their target price on Ultragenyx Pharmaceutical from $28.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, September 4th. Barclays raised their price target on Ultragenyx Pharmaceutical from $32.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, September 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $34.58.

Check Out Our Latest Report on RARE

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Ultragenyx Pharmaceutical Company Profile

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. The company targets conditions with limited or no treatment options, including metabolic disorders, skeletal diseases and other inherited conditions. Its work includes the development of medicines, biologic therapies and gene therapy candidates intended to address the underlying causes or significant symptoms of these disorders.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Dojolvi (triheptanoin), a medical food used to manage long-chain fatty acid oxidation disorders; and Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII.